A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase

Y. Sozmen, Eser; Elmas, Ömer Faruk; Demirbaş, Abdullah; LOTTI, TORELLO; Günay, Ümran; ilanbey, Bilal; Atasoy, Mustafa; tursen, umit

doi:10.3906/sag-2101-137

A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase

Bilal ILANBEY, (Ahi Evran Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Kırşehir, Türkiye)

Ömer Faruk ELMAS, (Kırıkkale Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Kırıkkale, Türkiye)

Eser Yıldırım SÖZMEN, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, İzmir, Türkiye)

Ümran GÜNAY, (Dermatoloji Anabilim Dalı, İstanbul Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Abdullah DEMİRBAŞ, (Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim ve Araştırma Hastanesi, Dermatoloji Anabilim Dalı, Kütahya, Türkiye)

Mustafa ATASOY, (Dermatoloji Anabilim Dalı, Kayseri Şehir Hastanesi, Sağlık Bilimleri Üniversitesi, Kayseri, Türkiye)

Ümit TÜRSEN, (Mersin Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Mersin, Türkiye)

Torello LOTTİ (Department of Dermatology, Faculty of Medicine, Guglielmo Marconi University, Rome, Italy)

Turkish Journal of Medical Sciences

2 0

Yıl: 2021 Cilt: 51 Sayı: 5 Sayfa Aralığı: 2318 - 2323 Metin Dili: İngilizce DOI: 10.3906/sag-2101-137 İndeks Tarihi: 06-01-2022

A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase

Öz:

Background/aim: Chitotriosidase (ChT) is an enzyme secreted by activated macrophages and neutrophils in response to proinflammatory signals. There is growing evidence indicating that ChT activity reflects the systemic inflammatory status. This study aimed to investigate whether serum ChT activity increased in patients with psoriasis and related comorbidities. Materials and methods: This cross-sectional study included 53 (28 with associated comorbidities and 25 without comorbidities) patients with psoriasis and 52 healthy volunteers. All participants underwent laboratory investigations for serum ChT levels, complete blood count, erythrocyte sedimentation rate, C-reactive protein, and serum lipid levels. Results: The patients with psoriasis showed significantly higher levels of ChT activity as compared to the healthy controls (23.5 ± 11.4 vs. 17.5 ± 10.4 μmol/mL/hour; p = 0.015). Additionally, the ChT activity was significantly higher in patients with comorbidities than in those without (p = 0.042). Conclusion: Our data support the pathogenetic role of inflammatory processes induced by macrophage activation in patients with psoriasis and related comorbidities. We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the possible related comorbidities.Keywords: Chitotriosidase, comorbidity, macrophage, psoriasis

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386 (9997): 983-994. doi: 10.1016/S0140-6736(14)61909-7
2. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences 2019; 20 (6) :1475. doi: 10.3390/ijms20061475
3. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie AS et al. Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology 2017; 76 (3) :377-390. doi: 10.1016/j.jaad.2016.07.064
4. Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE et al. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. British Journal of Dermatology 2017; 176 (3) :650-658. doi: 10.1111/bjd.15021
5. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation 1994; 93 (3) :1288-1292. doi: 10.1172/JCI117084
6. van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. International Immunology 2005; 17 (11) :1505-1512. doi: 10.1093/intimm/dxh328
7. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. Journal of Biological Chemistry 1995; 270 (44) :26252-26256. doi: 10.1074/jbc.270.44.26252
8. Malaguarnera L. Chitotriosidase: the yin and yang. Cellular and Molecular Life Sciences 2006; 63 (24) :3018-3029. doi: 10.1007/s00018-006-6269-2
9. Turan E, Sozmen B, Eltutan M, Sozmen EY. Serum chitotriosidase enzyme activity is closely related to HbA1c levels and the complications in patients with diabetes mellitus type 2. Diabetes and Metabolic Syndrome 2017; 11: S503-S506. doi: 10.1016/j.dsx.2017.03.044
10. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respiratory Research 2020; 21 (1) :6. doi: 10.1186/s12931-019-1263-z
11. Yildiz BS, Barutcuoglu B, Alihanoglu YI, Alkan MB, Bilgin M et al. Serum chitotriosidase activity in acute coronary syndrome. Journal of Atherosclerosis and Thrombosis 2013; 20 (2) :134- 141. doi: 10.5551/jat.13920
12. Thein MS, Kohli A, Ram R, Ingaramo MC, Jain A et al. Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer. Cancer Biomarkers 2013; 19 (4) :383-391. doi: 10.5551/jat.13920
13. Kologlu T, Ucar SK, Levent E, Akcay YD, Coker M et al. Chitotriosidase as a possible marker of clinically evidenced atherosclerosis in dyslipidemic children. Journal of Pediatric Endocrinology and Metabolism 2014; 27 (7-8) :701-708. doi: 10.1515/jpem-2013-0365
14. Boot RG, Blommaart EF, Swart E, Ghauharali-van der Vlugt K, Bijl N et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. Journal of Biological Chemistry 2001; 276 (9) :6770-6778. doi: 10.1074/jbc.M009886200
15. Artieda M, Cenarro A, Gañán A, Jericó I, Gonzalvo C et al. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23 (9) :1645-1652. doi: 10.1161/01.ATV.0000089329.09061.07
16. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research 2011; 303 (1) :1-10. doi: 10.1007/s00403-010-1080-1
17. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatologic Clinics 2015; 33 (1):13-23. doi: 10.1016/j.det.2014.09.002
18. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology 2012; 26; Suppl 2:3- 11. doi: 10.1111/j.1468-3083.2011.04410.x
19. James W, Berger TG, Elston D. Errors in metabolism. In: Andrews’ Diseases of the Skin. Clinical Dermatology. 10th ed. City, Canada: Saunders Elsevier; 2006. pp.
20. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. British Journal of Dermatology 2013; 168 (3) :486-495. doi: 10.1111/bjd.12101
21. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators of Inflammation 2010; 2010: 535612. doi: 10.1155/2010/535612
22. Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Dermato-Venereologica 2020; 100 (3) : adv00033. doi: 10.2340/00015555-3387
23. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology 2010; 130 (7): 1785-1796. doi: 10.1038/jid.2010.103
24. Sonmez A, Haymana C, Tapan S, Safer U, Celebi G et al. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine 2010; 37 (3): 455-459. doi: 10.1007/s12020-010-9334-4
25. Justin Rucker A, Crowley SD. The role of macrophages in hypertension and its complications. Pflügers Archiv: European Journal of Physiology 2017; 469 (3-4) :419-430. doi: 10.1007/s00424-017-1950-x
26. Ma WH, Wang XL, Du YM, Wang YB, Zhang Y et al. Association between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness in essential hypertension. BMC Cardiovascular Disorders 2012; 12:35. doi: 10.1186/1471-2261-12-35

APA	ilanbey B, Elmas Ö, Y. Sozmen E, Günay Ü, Demirbaş A, Atasoy M, tursen u, LOTTI T (2021). A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. , 2318 - 2323. 10.3906/sag-2101-137
Chicago	ilanbey Bilal,Elmas Ömer Faruk,Y. Sozmen Eser,Günay Ümran,Demirbaş Abdullah,Atasoy Mustafa,tursen umit,LOTTI TORELLO A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. (2021): 2318 - 2323. 10.3906/sag-2101-137
MLA	ilanbey Bilal,Elmas Ömer Faruk,Y. Sozmen Eser,Günay Ümran,Demirbaş Abdullah,Atasoy Mustafa,tursen umit,LOTTI TORELLO A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. , 2021, ss.2318 - 2323. 10.3906/sag-2101-137
AMA	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. . 2021; 2318 - 2323. 10.3906/sag-2101-137
Vancouver	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. . 2021; 2318 - 2323. 10.3906/sag-2101-137
IEEE	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T "A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase." , ss.2318 - 2323, 2021. 10.3906/sag-2101-137
ISNAD	ilanbey, Bilal vd. "A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase". (2021), 2318-2323. https://doi.org/10.3906/sag-2101-137

APA	ilanbey B, Elmas Ö, Y. Sozmen E, Günay Ü, Demirbaş A, Atasoy M, tursen u, LOTTI T (2021). A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences, 51(5), 2318 - 2323. 10.3906/sag-2101-137
Chicago	ilanbey Bilal,Elmas Ömer Faruk,Y. Sozmen Eser,Günay Ümran,Demirbaş Abdullah,Atasoy Mustafa,tursen umit,LOTTI TORELLO A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences 51, no.5 (2021): 2318 - 2323. 10.3906/sag-2101-137
MLA	ilanbey Bilal,Elmas Ömer Faruk,Y. Sozmen Eser,Günay Ümran,Demirbaş Abdullah,Atasoy Mustafa,tursen umit,LOTTI TORELLO A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences, vol.51, no.5, 2021, ss.2318 - 2323. 10.3906/sag-2101-137
AMA	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences. 2021; 51(5): 2318 - 2323. 10.3906/sag-2101-137
Vancouver	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase. Turkish Journal of Medical Sciences. 2021; 51(5): 2318 - 2323. 10.3906/sag-2101-137
IEEE	ilanbey B,Elmas Ö,Y. Sozmen E,Günay Ü,Demirbaş A,Atasoy M,tursen u,LOTTI T "A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase." Turkish Journal of Medical Sciences, 51, ss.2318 - 2323, 2021. 10.3906/sag-2101-137
ISNAD	ilanbey, Bilal vd. "A novel marker of systemic inflammation in psoriasis and related comorbidities: chitotriosidase". Turkish Journal of Medical Sciences 51/5 (2021), 2318-2323. https://doi.org/10.3906/sag-2101-137